<DOC>
	<DOCNO>NCT00121784</DOCNO>
	<brief_summary>Heart transplant patient standard care regimen CNI , MMF , corticosteroid enter study 4-6 week post-transplant . At 3 month transplant , patient randomize either continue regimen CNI therapy discontinue replaced sirolimus therapy ( combination MMF corticosteroid ) . The effect 2 regimen efficacy , safety renal function evaluated.The anticipated time study treatment 1-2 year target sample size 500+ individual .</brief_summary>
	<brief_title>Heart Spare Nephron ( STN ) Study - A Study CellCept ( Mycophenolate Mofetil ) Rapamune ( Sirolimus ) Heart Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>adult ( &gt; =18 year age ) heart transplant patient ( 46 week posttransplant ) ; receipt first heart ( singleorgan ) transplant ; standard care regimen CNI , MMF , corticosteroid since transplantation . positive donorspecific crossmatch time transplantation ; history malignancy , nonmelanoma skin cancer totally excise recurrence 2 year ; patient participate another interventional clinical trial require treatment unmarketed investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>